Research Department,Institute for Health Economics and Policy,Association for Health Economics Research and Social Insurance and Welfare,Tokyo,Japan.
Inaho Clinic,Kanagawa,Japan.
Int Psychogeriatr. 2015 Mar;27(3):407-15. doi: 10.1017/S1041610214001975. Epub 2014 Sep 12.
We aimed to examine trends in the use of psychotropic medications among elderly outpatients with dementia in Japan between 2002 and 2010.
We used data from the 2002-2010 Survey of Medical Care Activities in Public Health Insurance (SMCA-PHI), a nationally representative cross-sectional survey of claims data for the month of June in every year. We included ambulatory care visits by patients aged 65 years or older who were prescribed cholinesterase inhibitors (n = 15,591), and identified use of any psychotropic medications during the survey month.
In 2008–2010, the most prevalently prescribed psychotropic medications to patients with dementia were sedatives-hypnotics (27.3%), antipsychotics (21.3%), antidepressants (11.4%), and mood-stabilizers(2.8%). Between 2002–2004 and 2008–2010, use of second-generation antipsychotics increased from 4.9%to 11.2%, while use of first-generation antipsychotics decreased from 17.4% to 12.1% [corrected].These numbers resulted in a 1.1-fold increase in the adjusted prevalence of the overall use of antipsychotics. Quetiapine and risperidone use showed a 4.8- and 1.8-fold increase, respectively, while haloperidol use showed a 2.3-fold decrease.
Despite safety warnings against the use of antipsychotics for patients with dementia in several countries, our study revealed a slight increase in the extensive use of off-label antipsychotics over time in Japan. This finding indicates an urgent need for evaluation of the efficacy of antipsychotics for the approved treatment of severe agitation, aggression, and psychosis associated with dementia. Moreover, psychosocial interventions and antipsychotic withdrawal strategies are needed in order to reduce the overall prevalence of antipsychotic use.
本研究旨在探讨 2002 年至 2010 年期间,日本老年痴呆门诊患者中精神药物的使用趋势。
我们使用了 2002 年至 2010 年《公共医疗保险医疗活动调查》(SMCA-PHI)的数据,该调查是一项针对每年 6 月的全国代表性横断面调查。我们纳入了接受过胆碱酯酶抑制剂治疗的 65 岁及以上门诊患者的就诊记录(n=15591),并确定了在调查当月使用的任何精神药物。
2008 年至 2010 年,最常用于痴呆患者的精神药物是镇静催眠药(27.3%)、抗精神病药(21.3%)、抗抑郁药(11.4%)和心境稳定剂(2.8%)。2002 年至 2004 年至 2008 年至 2010 年期间,第二代抗精神病药的使用比例从 4.9%增加到 11.2%,第一代抗精神病药的使用比例从 17.4%下降到 12.1%[校正]。这导致抗精神病药总体使用率的调整后患病率增加了 1.1 倍。喹硫平和利培酮的使用分别增加了 4.8 倍和 1.8 倍,而氟哌啶醇的使用则减少了 2.3 倍。
尽管在多个国家对痴呆患者使用抗精神病药发出了安全警告,但我们的研究显示,在日本,随着时间的推移,非适应证使用抗精神病药的情况略有增加。这一发现表明,迫切需要评估抗精神病药治疗痴呆相关严重激越、攻击和精神病的疗效。此外,需要采用心理社会干预和抗精神病药撤药策略,以降低抗精神病药的总体使用率。